6 recruiting, 3 completed, 1 active not recruiting, 1 not yet recruiting. 3 Phase 3, 2 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Nivolumab + Relatlimab: new trials by email Literature Review of Nivolumab + Relatlimab trials Research Report on Nivolumab + Relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab Nivolumab + relatlimab, Nivolumab + ipilimumab - Melanoma | Completed | Bristol-Myers Squibb | 100 | 2025-05-11 | 2025-11-12 | |
| Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database Nivolumab + Relatlimab, Nivolumab + Ipilimumab, Immunotherapy monotherapy - Advanced Melanoma | Completed | Bristol-Myers Squibb | 678 | 2024-11-29 | 2025-07-23 | |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Replimune, Inc. | 400 | 2024-07-11 | 2026-07-15 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Brenetafusp, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 680 | 2024-06-05 | 2026-02-25 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
| Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Nivolumab, Ipilimumab, Nivolumab + Relatlimab - Metastatic Melanoma, Metastasis to Brain | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 1 | 2023-06-06 | 2026-04-06 |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma Nivolumab + Relatlimab, rHuPH20 - Melanoma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 579 | 2023-03-06 | 2026-08-26 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors Zanzalintinib, Nivolumab, Ipilimumab - Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Exelixis | 1394 | 2021-12-14 | 2026-10-01 |
| Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Carlo Contreras | 36 | 2021-10-20 | 2026-07-13 |
| Pan Tumor Rollover Study Nivolumab, Ipilimumab, Cabozantinib - Cancer | Phase 2 | Recruiting | Bristol-Myers Squibb | 1500 | 2019-08-09 | 2026-09-23 |
Melanoma (6) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Skin Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Bristol-Myers Squibb (5) · H. Lee Moffitt Cancer Center and Research Institute (2) · Carlo Contreras (1) · Exelixis (1) · Immunocore Ltd (1) · Replimune, Inc. (1)
United States (10) · France (5) · Germany (5) · Poland (5) · Spain (5) · United Kingdom (5) · Australia (4) · Austria (4) · Belgium (4) · Italy (4) · Switzerland (4) · Brazil (3) · Canada (3) · Czechia (3) · Finland (3)
Ahmad Tarhini, MD, PhD (1) · Carlo M Contreras, MD (1) · Jeannie Hou, MD (1) · Peter Forsyth, MD (1) · Yolanda Pina, MD (1)
2023 (2), 2018 (1)